Grastofil

Grastofil is a prescription medication that contains the active ingredient filgrastim, a recombinant granulocyte colony‑stimulating factor (G‑CSF). It is supplied in a sterile solution for intravenous or subcutaneous administration. As a hematopoietic growth factor, Grastofil stimulates the production and activation of neutrophil precursors, helping to raise neutrophil counts in patients with certain types of neutropenia. The product is marketed in the European Union region and is intended for clinical use.

Grastofil is indicated for several clinical situations in which neutrophil production is compromised.

- Management of chemotherapy‑induced neutropenia - Prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy - Treatment of neutropenia associated with bone marrow transplantation - Supportive therapy for patients with severe chronic neutropenia - Use in aplastic anemia when neutrophil recovery is needed

The safety profile of filgrastim includes both frequently observed and less common adverse reactions.

Common: - Bone pain at injection site or systemic - Redness, swelling, or itching at injection site - Headache - Fatigue or malaise - Low‑grade fever - Nausea or mild gastrointestinal upset

Serious: - Splenic rupture or enlargement - Acute respiratory distress syndrome (ARDS) - Severe allergic reactions including anaphylaxis - Capillary leak syndrome - Severe hypotension or shock

Healthcare providers should consider the following precautions when prescribing Grastofil.

- Assess baseline neutrophil count before initiation - Monitor for signs of splenic enlargement during therapy - Use caution in patients with known hypersensitivity to filgrastim or any excipient - Evaluate renal and hepatic function in patients with organ impairment - Avoid use in patients with active uncontrolled infection unless benefits outweigh risks - Consider dose adjustment in pediatric patients when appropriate - Counsel patients on proper injection technique to reduce local reactions

Grastofil may interact with other medications; awareness of potential interactions helps optimize safety.

Avoid: - Concurrent use with chemotherapy agents that cause severe myelosuppression may diminish efficacy - Concomitant administration with other colony‑stimulating factors may increase risk of bone pain

Use with caution: - Antimicrobial agents that can cause neutropenia (e.g., linezolid) may require monitoring - Corticosteroids may augment neutrophil response - Drugs affecting the immune system (e.g., immunosuppressants) may alter expected outcomes - Vaccines, especially live attenuated, should be administered with caution - Agents that affect platelet function may require additional observation